The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
Proceeds will be used to support studies for regulatory submissions to the FDA for the company's metastatic breast cancer test, among other things.
A new trial has compared the two most prominent tests, showing that both have clear predictive ability, but leaving several other questions unanswered so far.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The firm has developed microbubbles that bind to target molecules based on surface antibodies.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
The single approach could be useful in some of the same areas where combinations of technologies have been implemented, such as AR-V7 testing in prostate cancer.
Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.
The company saw a drop in its Q4 sample accessions compared to the same quarter last year, but posted increases in both testing and revenues for the full year.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.